Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chronic Noncommunicable Diseases

References

• Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013;62:3307–3315. doi:10.2337/db12-181424065788
   PubMed Web of Science ®Google Scholar
• McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harb Perspect Biol. 2013;5:a008656. doi:10.1101/cshperspect.a00865623545416
   PubMed Web of Science ®Google Scholar
• Black RA, Kronheim SR, Merriam JE, March CJ, Hopp TP. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin-1 beta. J Biol Chem. 1989;264:5323–5326.2784432
   PubMed Web of Science ®Google Scholar
• Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature. 1992;356:768–774. doi:10.1038/356768a01574116
   PubMed Web of Science ®Google Scholar
• Martinon F, Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007;14:10. doi:10.1038/sj.cdd.440203816977329
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell. 2002;10:417–426. doi:10.1016/S1097-2765(02)00599-312191486
   PubMed Web of Science ®Google Scholar
• Kayagaki N, Warming S, Lamkanfi M, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479:117–121. doi:10.1038/nature1055822002608
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550. doi:10.1146/annurev.immunol.021908.13261219302047
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Saltiel AR. Inflammatory links between obesity and metabolic disease. J Clin Invest. 2011;121:2111–2117. doi:10.1172/JCI5713221633179
   PubMed Web of Science ®Google Scholar
• Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–241. doi:10.1038/nature0451616407889
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228–232. doi:10.1038/nature0451516407890
   PubMed Web of Science ®Google Scholar
• Vandanmagsar B, Youm Y-H, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179. doi:10.1038/nm.227921217695
   PubMed Web of Science ®Google Scholar
• Kanneganti T-D, Özören N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature. 2006;440:233–236. doi:10.1038/nature0451716407888
   PubMed Web of Science ®Google Scholar
• Zhong YK, Saleh M. FunctionsofNOD-likereceptorsinhumandiseases. Front Immunol. 2013;4:333.24137163
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–867. doi:10.1038/nature0548517167474
   PubMed Web of Science ®Google Scholar
• Suganami T, Tanaka M, Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J. 2012;EJ12–E0271.
   Web of Science ®Google Scholar
• Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem Cell Biol. 2004;82:170–190. doi:10.1139/o03-07815052336
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, Van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005;365:1333–1346. doi:10.1016/S0140-6736(05)61032-X15823385
   PubMed Web of Science ®Google Scholar
• Fève B, Bastard J-P. The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:305. doi:10.1038/nrendo.2009.6219399017
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA, Lewis E, et al. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med. 2006;12:650–656. doi:10.1038/nm141516732281
   PubMed Web of Science ®Google Scholar
• Ekpenyong C, Udokang NE, Akpan E, Samson T. Double burden, non-communicable diseases and risk factors evaluation in sub-Saharan Africa: the Nigerian experience. Eur J Sustain Dev. 2012;1:249. doi:10.14207/ejsd.2012.v1n2p249
   Google Scholar
• Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi:10.1016/S0140-6736(17)32152-928919116
   PubMed Web of Science ®Google Scholar
• Alzeidan R, Rabiee F, Mandil A, Hersi A, Fayed A. Non-communicable disease risk factors among employees and their families of a Saudi university: an epidemiological study. PLoS One. 2016;11:e0165036. doi:10.1371/journal.pone.016503627814369
   PubMed Web of Science ®Google Scholar
• Koenen TB, Stienstra R, Van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1β transcription in human adipose tissue. Diabetes. 2011;60:517–524. doi:10.2337/db10-026621270263
   PubMed Web of Science ®Google Scholar
• Organization WH. Preventing Noncommunicable Diseases (Ncds) by Reducing Environmental Risk Factors. World Health Organization; 2017.
   Google Scholar
• Fernández DJ, Lamkanfi M. Inflammatory caspases: key regulators of inflammation and cell death. Biol Chem. 2015;396:193–203. doi:10.1515/hsz-2014-025325389992
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013–1022. doi:10.1016/j.cell.2014.04.00724855941
   PubMed Web of Science ®Google Scholar
• Lamkanfi M. Emerging inflammasome effector mechanisms. Nat Rev Immunol. 2011;11:213–220. doi:10.1038/nri293621350580
   PubMed Web of Science ®Google Scholar
• Saleh M. The machinery of Nod‐like receptors: refining the paths to immunity and cell death. Immunol Rev. 2011;243:235–246. doi:10.1111/j.1600-065X.2011.01045.x21884180
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411. doi:10.1038/nri345223702978
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The inflammasomes. cell. 2010;140:821–832. doi:10.1016/j.cell.2010.01.04020303873
   PubMed Web of Science ®Google Scholar
• Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. nature. 2012;481:278–286. doi:10.1038/nature1075922258606
   PubMed Web of Science ®Google Scholar
• Muñoz-Planillo R, Kuffa P, Martínez-Colón G, Smith BL, Rajendiran TM, Núñez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38:1142–1153. doi:10.1016/j.immuni.2013.05.01623809161
   PubMed Web of Science ®Google Scholar
• Brodsky IE, Monack D NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens. Seminars in Immunology Elsevier; 2009:199–207.
   Google Scholar
• Próchnicki T, Latz E. Inflammasomes on the crossroads of innate immune recognition and metabolic control. Cell Metab. 2017;26:71–93. doi:10.1016/j.cmet.2017.06.01828683296
   PubMed Web of Science ®Google Scholar
• Zhang D, Lin J, Han J. Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol. 2010;7:243–249. doi:10.1038/cmi.2010.1020383176
   PubMed Web of Science ®Google Scholar
• Tenthorey JL, Kofoed EM, Daugherty MD, Malik HS, Vance RE. Molecular basis for specific recognition of bacterial ligands by NAIP/NLRC4 inflammasomes. Mol Cell. 2014;54:17–29. doi:10.1016/j.molcel.2014.02.01824657167
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Yu J-W, Datta P, Wu J, Alnemri ES. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458:509–513. doi:10.1038/nature0771019158676
   PubMed Web of Science ®Google Scholar
• Jin T, Perry A, Jiang J, et al. Structures of the HIN domain: DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity. 2012;36:561–571. doi:10.1016/j.immuni.2012.02.01422483801
   PubMed Web of Science ®Google Scholar
• Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell. 2016;165:792–800. doi:10.1016/j.cell.2016.03.04627153493
   PubMed Web of Science ®Google Scholar
• von Moltke J, Ayres JS, Kofoed EM, Chavarría-Smith J, Vance RE. Recognition of bacteria by inflammasomes. Annu Rev Immunol. 2013;31:73–106. doi:10.1146/annurev-immunol-032712-09594423215645
   PubMed Web of Science ®Google Scholar
• Sharma D, Kanneganti T-D. The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation. J Cell Biol. 2016;213:617–629. doi:10.1083/jcb.20160208927325789
   PubMed Web of Science ®Google Scholar
• Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10:241–247.19221555
   PubMed Web of Science ®Google Scholar
• Henao-Mejia J, Elinav E, Jin -C-C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179. doi:10.1038/nature1080922297845
   PubMed Web of Science ®Google Scholar
• Ke Z, Liang D, Zeng Q, et al. hsBAFF promotes proliferation and survival in cultured B lymphocytes via calcium signaling activation of mTOR pathway. Cytokine. 2013;62:310–321. doi:10.1016/j.cyto.2013.03.01123557796
   PubMed Web of Science ®Google Scholar
• McGettrick A, O’neill L. NLRP3 and IL‐1β in macrophages as critical regulators of metabolic diseases. Diabetes Obes Metab. 2013;15:19–25. doi:10.1111/dom.1216924003917
   PubMed Web of Science ®Google Scholar
• Keller M, Rüegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 2008;132:818–831. doi:10.1016/j.cell.2007.12.04018329368
   PubMed Web of Science ®Google Scholar
• Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7:99–109. doi:10.1038/nrmicro207019148178
   PubMed Web of Science ®Google Scholar
• Molla MD, Ayelign B, Dessie G, Geto Z, Admasu TD. Caspase-1 as a regulatory molecule of lipid metabolism. Lipids Health Dis. 2020;19:1–7. doi:10.1186/s12944-020-01220-y31900179
   PubMed Web of Science ®Google Scholar
• Skeldon AM, Faraj M, Saleh M. Caspases and inflammasomes in metabolic inflammation. Immunol Cell Biol. 2014;92:304. doi:10.1038/icb.2014.524518981
   PubMed Web of Science ®Google Scholar
• Geto Z, Molla MD, Challa F, Belay Y, Getahun T. Mitochondrial dynamic dysfunction as a main triggering factor for inflammation associated chronic non-communicable diseases. J Inflamm Res. 2020;13:97. doi:10.2147/JIR.S23200932110085
   PubMed Web of Science ®Google Scholar
• Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am. 2008;37:603–621. doi:10.1016/j.ecl.2008.05.00118775354
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–184. doi:10.1172/JCI2988117200717
   PubMed Web of Science ®Google Scholar
• Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010;12:593–605. doi:10.1016/j.cmet.2010.11.01121109192
   PubMed Web of Science ®Google Scholar
• Stienstra R, Van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci. 2011;108:15324–15329. doi:10.1073/pnas.110025510821876127
   PubMed Web of Science ®Google Scholar
• Wang H, Capell W, Yoon J, Faubel S, Eckel R. Obesity development in caspase-1-deficient mice. Int J Obes. 2014;38:152–155. doi:10.1038/ijo.2013.59
   Web of Science ®Google Scholar
• Murphy AJ, Kraakman MJ, Kammoun HL, et al. IL-18 production from the NLRP1 inflammasome prevents obesity and metabolic syndrome. Cell Metab. 2016;23:155–164. doi:10.1016/j.cmet.2015.09.02426603191
   PubMed Web of Science ®Google Scholar
• Lindegaard B, Matthews VB, Brandt C, et al. Interleukin-18 activates skeletal muscle AMPK and reduces weight gain and insulin resistance in mice. Diabetes. 2013;62:3064–3074. doi:10.2337/db12-109523670974
   PubMed Web of Science ®Google Scholar
• Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol. 1999;103:11–24. doi:10.1016/S0091-6749(99)70518-X9893178
   PubMed Web of Science ®Google Scholar
• Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15:635–645. doi:10.1016/j.cmet.2012.04.00122560216
   PubMed Web of Science ®Google Scholar
• Wellen K, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111–1119. doi:10.1172/JCI2510215864338
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808. doi:10.1172/JCI20031924614679176
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830. doi:10.1172/JCI20031945114679177
   PubMed Web of Science ®Google Scholar
• Wen H, Gris D, Lei Y, et al. Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408. doi:10.1038/ni.202221478880
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep. 2005;5:70–75. doi:10.1007/s11892-005-0071-715663921
   PubMedGoogle Scholar
• Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772–783. doi:10.1038/nri193716998510
   PubMed Web of Science ®Google Scholar
• Chalkiadaki A, Guarente L. High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 2012;16:180–188.22883230
   PubMed Web of Science ®Google Scholar
• Yin Y, Li X, Sha X, et al. Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol. 2015;115:305282.
   Google Scholar
• Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun. 1999;260:273–279. doi:10.1006/bbrc.1999.089710381378
   PubMed Web of Science ®Google Scholar
• Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-γ. Nature. 2004;429:771. doi:10.1038/nature0258315175761
   PubMed Web of Science ®Google Scholar
• Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009;29:1363–1374. doi:10.1128/MCB.00705-0819103747
   PubMed Web of Science ®Google Scholar
• Walker AK, Yang F, Jiang K, et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 2010;24:1403–1417. doi:10.1101/gad.190121020595232
   PubMed Web of Science ®Google Scholar
• Ponugoti B, Kim D-H, Xiao Z, et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010;285:33959–33970. doi:10.1074/jbc.M110.12297820817729
   PubMed Web of Science ®Google Scholar
• Shibabaw T, Dessie G, Molla MD, Zerihun MF, Ayelign B. Assessment of liver marker enzymes and its association with type 2 diabetes mellitus in Northwest Ethiopia. BMC Res Notes. 2019;12:707. doi:10.1186/s13104-019-4742-x31665087
   PubMedGoogle Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88.29219149
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.10784331518657
   PubMed Web of Science ®Google Scholar
• Ogurtsova K, da Rocha Fernandes J, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi:10.1016/j.diabres.2017.03.02428437734
   PubMed Web of Science ®Google Scholar
• Alberti KGM, Zimmet P. Epidemiology: global burden of disease—where does diabetes mellitus fit in? Nat Rev Endocrinol. 2013;9:258. doi:10.1038/nrendo.2013.5423478328
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–846. doi:10.1038/nature0548217167471
   PubMed Web of Science ®Google Scholar
• Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol. 2010;72:219–246. doi:10.1146/annurev-physiol-021909-13584620148674
   PubMed Web of Science ®Google Scholar
• Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–109. doi:10.1016/j.cyto.2016.06.02827498215
   PubMed Web of Science ®Google Scholar
• King GL. The role of inflammatory cytokines in diabetes and its complications. J Periodontol. 2008;79:1527–1534. doi:10.1902/jop.2008.08024618673007
   PubMed Web of Science ®Google Scholar
• Rivero-González A, Martín-Izquierdo E, Marín-Delgado C, Rodríguez-Muñoz A, Navarro-González JF. Cytokines in diabetes and diabetic complications In: Cytokine Effector Functions in Tissues. Elsevier; 2017:119–128.
   Google Scholar
• Williams MD, Nadler JL. Inflammatory mechanisms of diabetic complications. Curr Diab Rep. 2007;7:242–248. doi:10.1007/s11892-007-0038-y17547842
   PubMedGoogle Scholar
• Rodrigues KF, Pietrani NT, Bosco AA, Campos FMF, Sandrim VC, Gomes KB. IL-6, TNF-α, and IL-10 levels/polymorphisms and their association with type 2 diabetes mellitus and obesity in Brazilian individuals. Arch Endocrinol Metab. 2017;61:438–446. doi:10.1590/2359-399700000025428225860
   PubMed Web of Science ®Google Scholar
• Gupta S, Maratha A, Siednienko J, et al. Analysis of inflammatory cytokine and TLR expression levels in type 2 diabetes with complications. Sci Rep. 2017;7:7633.28794498
   PubMed Web of Science ®Google Scholar
• Donath MY, Böni-Schnetzler M, Ellingsgaard H, Halban PA, Ehses JA. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol Metab. 2010;21:261–267. doi:10.1016/j.tem.2009.12.01020096598
   PubMed Web of Science ®Google Scholar
• Donath MY, Dalmas É, Sauter NS, Böni-Schnetzler M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 2013;17:860–872. doi:10.1016/j.cmet.2013.05.00123747245
   PubMed Web of Science ®Google Scholar
• Stratford S, Hoehn KL, Liu F, Summers SA. Regulation of insulin action by ceramide dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem. 2004;279:36608–36615. doi:10.1074/jbc.M40649920015220355
   PubMed Web of Science ®Google Scholar
• Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes. 2010;59:2453–2464. doi:10.2337/db09-129320522596
   PubMed Web of Science ®Google Scholar
• Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118:2992–3002. doi:10.1172/JCI3426018769626
   PubMed Web of Science ®Google Scholar
• Jager J, Grémeaux T, Cormont M, Le Marchand-brustel Y, Tanti J-F. Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007;148:241–251. doi:10.1210/en.2006-069217038556
   PubMed Web of Science ®Google Scholar
• Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003;52:2784–2789. doi:10.2337/diabetes.52.11.278414578297
   PubMed Web of Science ®Google Scholar
• Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J Biol Chem. 2002;277:48115–48121. doi:10.1074/jbc.M20945920012351658
   PubMed Web of Science ®Google Scholar
• Stephens J, Pekala P. Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem. 1992;267:13580–13584.1618860
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 1986;232:1545–1547. doi:10.1126/science.30869773086977
   PubMed Web of Science ®Google Scholar
• Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136–140. doi:10.1038/ni.183120023662
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol. 2009;187:61–70. doi:10.1083/jcb.20090312419805629
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1–receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517–1526. doi:10.1056/NEJMoa06521317429083
   PubMed Web of Science ®Google Scholar
• Mendis S, Puska P, Norrving B; Organization WH. Global Atlas on Cardiovascular Disease Prevention and Control. World Health Organization; 2011.
   Google Scholar
• Merkle S, Frantz S, Schön MP, et al. A role for caspase-1 in heart failure. Circ Res. 2007;100:645–653. doi:10.1161/01.RES.0000260203.55077.6117303764
   PubMed Web of Science ®Google Scholar
• Syed FM, Hahn HS, Odley A, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005;96:1103–1109.15845887
   PubMed Web of Science ®Google Scholar
• Rauf A, Shah M, Yellon DM, Davidson SM. Role of caspase 1 in ischemia/reperfusion injury of the myocardium. J Cardiovasc Pharmacol. 2019;74:194–200. doi:10.1097/FJC.000000000000069431356550
   PubMed Web of Science ®Google Scholar
• Frantz S, Ducharme A, Sawyer D, et al. Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction. J Mol Cell Cardiol. 2003;35:685–694. doi:10.1016/S0022-2828(03)00113-512788386
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL‐1β and IL‐18: inflammatory markers or mediators of hypertension? Br J Pharmacol. 2014;171:5589–5602. doi:10.1111/bph.1287625117218
   PubMed Web of Science ®Google Scholar
• Fujita T. Mechanisms of salt induced hypertension: focus on adrenal and sympathetic nervous system. J Am Soc Nephrol. 2014;25:1148–1155. doi:10.1681/ASN.201312125824578129
   PubMed Web of Science ®Google Scholar
• Qi J, Zhao X-F, Yu X-J, et al. Targeting interleukin-1 beta to suppress sympathoexcitation in hypothalamic paraventricular nucleus in dahl salt-sensitive hypertensive rats. Cardiovasc Toxicol. 2016;16:298–306. doi:10.1007/s12012-015-9338-726304161
   PubMed Web of Science ®Google Scholar
• Zheng F, Xing S, Gong Z, Mu W, Xing Q. Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Mediators Inflamm. 2014;2014:1–8. doi:10.1155/2014/507208
   Web of Science ®Google Scholar
• Usui F, Shirasuna K, Kimura H, et al. Critical role of caspase-1 in vascular inflammation and development of atherosclerosis in Western diet-fed apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2012;425:162–168. doi:10.1016/j.bbrc.2012.07.05822819845
   PubMed Web of Science ®Google Scholar
• Peng K, Liu L, Wei D, et al. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation. Int J Mol Med. 2015;35:1179–1188. doi:10.3892/ijmm.2015.212925761252
   PubMed Web of Science ®Google Scholar
• Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–1361. doi:10.1038/nature0893820428172
   PubMed Web of Science ®Google Scholar
• Lu J, Mitra S, Wang X, Khaidakov M, Mehta JL. Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal. 2011;15:2301–2333. doi:10.1089/ars.2010.379221338316
   PubMed Web of Science ®Google Scholar
• Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018;113:5. doi:10.1007/s00395-017-0663-929224086
   PubMed Web of Science ®Google Scholar
• Wu D, Ren P, Zheng Y, et al. NLRP3 (nucleotide oligomerization domain–like receptor family, pyrin domain containing 3)–caspase-1 inflammasome degrades contractile proteins: implications for aortic biomechanical dysfunction and aneurysm and dissection formation. Arterioscler Thromb Vasc Biol. 2017;37:694–706. doi:10.1161/ATVBAHA.116.30764828153878
   PubMed Web of Science ®Google Scholar
• Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors? Am Heart Assoc. 2010.
   PubMedGoogle Scholar
• Saxena A, Chen W, Su Y, et al. IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium. J Immunol. 2013;191:4838–4848. doi:10.4049/jimmunol.130072524078695
   PubMed Web of Science ®Google Scholar
• Toldo S, Mezzaroma E, Mauro AG, Salloum F, Van Tassell BW, Abbate A. The inflammasome in myocardial injury and cardiac remodeling. Antioxid Redox Signal. 2015;22:1146–1161. doi:10.1089/ars.2014.598925330141
   PubMed Web of Science ®Google Scholar
• Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594–604. doi:10.1161/CIRCULATIONAHA.110.98277721282498
   PubMed Web of Science ®Google Scholar
• Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol. 1997;151:317.9250144
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.30207593
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. cell. 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-910647931
   PubMed Web of Science ®Google Scholar
• Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 1995;4:85–92.7742727
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi:10.1016/j.cell.2010.01.02520303878
   PubMed Web of Science ®Google Scholar
• Schäfer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol. 2008;9:628–638. doi:10.1038/nrm245518628784
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.12490959
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22. doi:10.1038/nrc125214708024
   PubMed Web of Science ®Google Scholar
• Wen H, Ting JP-Y, O’Neill LAJ. A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? Nat Immunol. 2012;13(4):352–357. doi:10.1038/ni.222822430788
   PubMed Web of Science ®Google Scholar
• Guo B, Li Z. Endoplasmic reticulum stress in hepatic steatosis and inflammatory bowel diseases. Front Genet. 2014;5:242. doi:10.3389/fgene.2014.0024225120559
   PubMed Web of Science ®Google Scholar
• Molla MD, Dessie G, Akalu Y, Ayelign B. Hepatocellular expression of SIRT1 and its effect on hepatocellular carcinoma progression: a future therapeutic perspective. Int J Hepatol. 2020;2020.
   PubMed Web of Science ®Google Scholar
• Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61:1227–1232.11221855
   PubMed Web of Science ®Google Scholar
• Allen IC, TeKippe EM, Woodford R-MT, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med. 2010;207:1045–1056. doi:10.1084/jem.2010005020385749
   PubMed Web of Science ®Google Scholar
• Feng Q, Li P, Salamanca C, Huntsman D, Leung PC, Auersperg N. Caspase-1α is down-regulated in human ovarian cancer cells and the overexpression of caspase-1α induces apoptosis. Cancer Res. 2005;65:8591–8596. doi:10.1158/0008-5472.CAN-05-023916204022
   PubMed Web of Science ®Google Scholar
• Xia X, Wang X, Cheng Z, et al. The role of pyroptosis in cancer: pro-cancer or pro-“host”? Cell Death Dis. 2019;10:1–13. doi:10.1038/s41419-019-1883-8
   Web of Science ®Google Scholar
• Sun Y, Peng Z. Programmed cell death and cancer. Postgrad Med J. 2009;85:134–140. doi:10.1136/pgmj.2008.07262919351640
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–1916. doi:10.1128/IAI.73.4.1907-1916.200515784530
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Caspase‐1‐dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8:1812–1825. doi:10.1111/j.1462-5822.2006.00751.x16824040
   PubMed Web of Science ®Google Scholar
• Bergsbaken T, Cookson BT. Macrophage activation redirects yersinia-infected host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS Pathog. 2007;3:e161. doi:10.1371/journal.ppat.003016117983266
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol. 2012;13:343. doi:10.1038/ni.222422430787
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19:57–64. doi:10.1038/nm.299923202296
   PubMed Web of Science ®Google Scholar
• Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1β induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell. 2008;14:408–419. doi:10.1016/j.ccr.2008.10.01118977329
   PubMed Web of Science ®Google Scholar
• Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016;6:1–12.28442746
   PubMed Web of Science ®Google Scholar
• Chen GY, Liu M, Wang F, Bertin J, Núñez G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J Immunol. 2011;186:7187–7194. doi:10.4049/jimmunol.110041221543645
   PubMed Web of Science ®Google Scholar
• Allen IC, Wilson JE, Schneider M, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity. 2012;36:742–754. doi:10.1016/j.immuni.2012.03.01222503542
   PubMed Web of Science ®Google Scholar
• Hu B, Elinav E, Huber S, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci. 2010;107:21635–21640. doi:10.1073/pnas.101681410821118981
   PubMed Web of Science ®Google Scholar
• Marnett LJ. Oxyradicals and DNA damage. carcinogenesis. 2000;21:361–370.10688856
   PubMed Web of Science ®Google Scholar
• Covey TM, Edes K, Coombs GS, Virshup DM, Fitzpatrick FA. Alkylation of the tumor suppressor PTEN activates Akt and β-catenin signaling: a mechanism linking inflammation and oxidative stress with cancer. PLoS One. 2010;5:e13545. doi:10.1371/journal.pone.001354520975834
   PubMed Web of Science ®Google Scholar
• Isokawa O, Suda T, Aoyagi Y, et al. Reduction of telomeric repeats as a possible predictor for development of hepatocellular carcinoma: convenient evaluation by slot‐blot analysis. Hepatology. 1999;30:408–412. doi:10.1002/hep.51030021110421648
   PubMed Web of Science ®Google Scholar
• Hou L, Savage SA, Blaser MJ, et al. Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiol Biomarkers Prev. 2009;18:3103–3109. doi:10.1158/1055-9965.EPI-09-034719861514
   PubMed Web of Science ®Google Scholar
• Yang Y, Fruehauf J, Xiang S, Li CJ. Genomic instability in precancerous lesions before inactivation of tumor suppressors p53 and APC in patients. Cell Cycle. 2006;5:1443–1447. doi:10.4161/cc.5.13.289716855398
   PubMed Web of Science ®Google Scholar
• Güngör N, Haegens A, Knaapen AM, et al. Lung inflammation is associated with reduced pulmonary nucleotide excision repair in vivo. Mutagenesis. 2010;25:77–82. doi:10.1093/mutage/gep04919917589
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11–19. doi:10.1016/j.cytogfr.2009.11.00520018552
   PubMed Web of Science ®Google Scholar
• Ghosh S, Karin M. Missing pieces in the NFkB puzzle. Cell. 2002;109:S81–S96. doi:10.1016/S0092-8674(02)00703-111983155
   PubMed Web of Science ®Google Scholar
• Porta C, Riboldi E, Sica A. Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2011;305:250–262. doi:10.1016/j.canlet.2010.10.01221093147
   PubMed Web of Science ®Google Scholar
• Billiau A. Anti-inflammatory properties of Type I interferons. Antiviral Res. 2006;71:108–116. doi:10.1016/j.antiviral.2006.03.00616626815
   PubMed Web of Science ®Google Scholar
• Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity. 2011;34:213–223. doi:10.1016/j.immuni.2011.02.00621349431
   PubMed Web of Science ®Google Scholar
• Guarda G, Dostert C, Staehli F, et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature. 2009;460:269–273. doi:10.1038/nature0810019494813
   PubMed Web of Science ®Google Scholar
• Janczy JR Mechanisms for activation and inhibition of inflammasomes. 2014.
   Google Scholar
• Mishra BB, Rathinam VA, Martens GW, et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome–dependent processing of IL-1β. Nat Immunol. 2013;14:52–60.23160153
   PubMed Web of Science ®Google Scholar
• Zahid A, Li B, Kombe JK, Jin T, Tao J. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019;10:2538. doi:10.3389/fimmu.2019.0253831749805
   PubMed Web of Science ®Google Scholar
• He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289:1142–1150. doi:10.1074/jbc.M113.51508024265316
   PubMed Web of Science ®Google Scholar
• Marchetti C, Swartzwelter B, Gamboni F, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci. 2018;115:E1530–E9. doi:10.1073/pnas.171609511529378952
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Dixit VM. A new lead to NLRP3 inhibition. J Exp Med. 2017;214:3147. doi:10.1084/jem.2017184829061692
   PubMed Web of Science ®Google Scholar
• Marchetti C, Toldo S, Chojnacki J, et al. Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse. J Cardiovasc Pharmacol. 2015;66:1. doi:10.1097/FJC.000000000000024725915511
   PubMed Web of Science ®Google Scholar
• Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. 2015;26:409–421. doi:10.1097/MCA.000000000000025525946654
   PubMed Web of Science ®Google Scholar
• Karki R, Man SM, Kanneganti T-D. Inflammasomes and cancer. Cancer Immunol Res. 2017;5:94–99. doi:10.1158/2326-6066.CIR-16-026928093447
   PubMed Web of Science ®Google Scholar
• Perregaux DG, McNiff P, Laliberte R, et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharm Exp Ther. 2001;299:187–197.
   PubMed Web of Science ®Google Scholar
• He H, Jiang H, Chen Y, et al. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:1–12. doi:10.1038/s41467-018-04947-629317637
   PubMed Web of Science ®Google Scholar
• Fulp J, He L, Toldo S, et al. Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J Med Chem. 2018;61:5412–5423. doi:10.1021/acs.jmedchem.8b0073329877709
   PubMed Web of Science ®Google Scholar
• Liu W, Guo W, Wu J, et al. A novel benzo [d] imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. 2013;85:1504–1512. doi:10.1016/j.bcp.2013.03.00823506741
   PubMed Web of Science ®Google Scholar
• Boxer MB, Shen M, Auld DS, Wells JA, Thomas CJ A small molecule inhibitor of Caspase 1. Probe Reports from the NIH Molecular Libraries Program [Internet]. National Center for Biotechnology Information (US); 2011.
   Google Scholar
• Juliana C, Fernandes-Alnemri T, Wu J, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem. 2010;285:9792–9802. doi:10.1074/jbc.M109.08230520093358
   PubMed Web of Science ®Google Scholar